Antiplatelet monotherapy reduced bleeding but dual therapy provided greater cardiovascular event protection in patients at high ischaemic risk who had undergone stent implantation 12 months earlier. These results, from the A-CLOSE trial, were presented in a Hot Line session today at ESC Congress 2026 and were published simultaneously in the New England Journal of Medicine.

Prasugrel reduced major cardiovascular events to the same extent as ticagrelor but with lower major bleeding after coronary stenting in patients with acute coronary syndromes, according to results from the SWITCH SWEDEHEART trial presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine. 

Monotherapy using prasugrel failed to show noninferiority compared with potent antiplatelet therapy plus aspirin at the time of primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. This was the main finding of the PREMIUM trial presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine. 

Milvexian did not reduce major adverse cardiovascular events compared with placebo after a recent acute coronary syndrome and there was no increase in intracranial or fatal bleeding. These were the main findings from the LIBREXIA ACS trial presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine. The results follow a decision to discontinue the trial in November 2025 due to futility at a preplanned interim analysis. 

Silent atherosclerosis was detectable from early adulthood and showed sex-specific patterns of growth with age, according to results from the REACT study presented in a Hot Line session today at ESC Congress 20261 and published simultaneously in the New England Journal of Medicine. 

Phase 2 TRANQUILITY trial results presented by Mount Sinai investigator support further evaluation of pacibekitug in cardiovascular disease

Atorvastatin reduce​​d​​ major cardiovascular events by 30% in older people without known cardiovascular disease, diabetes or dementia, but did not significantly improve disability-free survival, according to results presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine. 

**Note this is an early release from the Annual Meeting of the European Association for the Study of Diabetes [EASD]. Please credit the meeting when using this research**

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) estimates the number of people living with type 1 diabetes (T1D) worldwide will increase by 29% from 9.4 million in 2025 to 12.1 million in 2049. In addition, it is estimated that the number of new cases per year will increase by 14% across this same period. The development of these estimates, using the DIAMOND-T1D model, has been led by Professor Anders Green, Steno Diabetes Center Odense, Denmark.